Published in Mol Cancer on December 20, 2010
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci (2012) 1.44
miRNAs and estrogen action. Trends Endocrinol Metab (2012) 1.24
The role of microRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci (2012) 1.24
Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene (2012) 1.18
MicroRNAs in cancer treatment and prognosis. Am J Cancer Res (2012) 1.17
Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res (2015) 1.12
Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med (2013) 1.11
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res (2012) 1.11
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem (2011) 1.10
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res (2015) 1.08
Role of microRNAs in breast cancer. Cancer Biol Ther (2013) 1.07
MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment. World J Clin Oncol (2014) 1.03
Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res (2012) 1.01
RNA-protein analysis using a conditional CRISPR nuclease. Proc Natl Acad Sci U S A (2013) 1.00
Functional profiling of precursor MicroRNAs identifies MicroRNAs essential for glioma proliferation. PLoS One (2013) 0.99
MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol (2014) 0.96
MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ. Sci Rep (2015) 0.96
MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol (2014) 0.96
miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets. Mol Cell Endocrinol (2015) 0.94
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res (2015) 0.93
Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med Press) (2015) 0.93
Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther (2014) 0.92
A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-α and ERK2 that controls breast cancer proliferation and invasiveness properties. Horm Cancer (2012) 0.90
Multiple tumor suppressor microRNAs regulate telomerase and TCF7, an important transcriptional regulator of the Wnt pathway. PLoS One (2014) 0.89
miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer. Exp Ther Med (2013) 0.87
miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. PLoS One (2014) 0.87
MicroRNA and cancer chemoprevention. Cancer Prev Res (Phila) (2013) 0.86
Alterations of microRNA expression patterns in human cervical carcinoma cells (Ca Ski) toward 1'S-1'-acetoxychavicol acetate and cisplatin. Reprod Sci (2012) 0.85
MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res (2012) 0.85
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. Int J Mol Sci (2015) 0.85
MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance. PLoS One (2014) 0.84
In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers. Cancer Inform (2013) 0.84
MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B (2015) 0.84
Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer (2015) 0.81
Tamoxifen Resistance: Emerging Molecular Targets. Int J Mol Sci (2016) 0.80
Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer (2015) 0.80
miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep (2015) 0.79
CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. Sci Rep (2016) 0.79
Decoding the usefulness of non-coding RNAs as breast cancer markers. J Transl Med (2016) 0.78
Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review). Oncol Lett (2013) 0.78
miRNA - Therapeutic tool in breast cancer? Where are we now? Rep Pract Oncol Radiother (2014) 0.78
Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis (2016) 0.77
Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. Oncotarget (2016) 0.77
miRNA-342 Regulates CEACAM1-induced Lumen Formation in a Three-dimensional Model of Mammary Gland Morphogenesis. J Biol Chem (2016) 0.76
Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin Cancer Res (2016) 0.76
The IL-4/STAT6 signaling axis establishes a conserved microRNA signature in human and mouse macrophages regulating cell survival via miR-342-3p. Genome Med (2016) 0.76
Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget (2016) 0.75
miRNA clusters as therapeutic targets for hormone-resistant breast cancer. Expert Rev Endocrinol Metab (2015) 0.75
A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model. PLoS One (2016) 0.75
Long-term exposure of MCF-7 breast cancer cells to ethanol stimulates oncogenic features. Int J Oncol (2016) 0.75
miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer. Oncotarget (2016) 0.75
Estrogen receptor negativity in breast cancer: A cause or consequence? Biosci Rep (2016) 0.75
MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. Oncotarget (2016) 0.75
Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma. Sci Rep (2016) 0.75
miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells. Oncotarget (2016) 0.75
Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet (2016) 0.75
ApoptomiRs of Breast Cancer: Basics to Clinics. Front Genet (2016) 0.75
MicroRNA expression profiling of human blood monocyte subsets highlights functional differences. Immunology (2015) 0.75
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Switching from repression to activation: microRNAs can up-regulate translation. Science (2007) 17.00
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst (2004) 6.55
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res (2007) 5.25
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem (2006) 4.59
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem (2008) 4.56
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol (2000) 2.96
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol (2005) 2.95
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res (2009) 2.59
Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol (2005) 2.49
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res (2009) 2.27
Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene (2008) 2.26
VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene (2003) 2.08
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res (2009) 1.98
Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res (2006) 1.67
Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Res (2004) 1.58
Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res (2003) 1.48
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol (2000) 1.47
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther (2009) 1.39
Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res (2001) 1.37
High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer (2009) 1.33
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics (2008) 1.25
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res (2008) 1.23
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res (2007) 1.15
Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol (2009) 1.12
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer (2008) 1.03
Involvement of microRNAs in breast cancer. Semin Reprod Med (2008) 0.99
Hyperglycemia-induced thioredoxin-interacting protein expression differs in breast cancer-derived cells and regulates paclitaxel IC50. Clin Cancer Res (2007) 0.88
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (2009) 3.77
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle (2009) 3.34
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol (2005) 2.95
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther (2009) 2.50
The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol (2004) 2.41
The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res (2006) 2.38
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res (2006) 1.94
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res (2010) 1.94
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol (2009) 1.84
Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development (2003) 1.79
Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res (2006) 1.78
Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res (2011) 1.74
Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res (2006) 1.67
Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. J Biol Chem (2005) 1.57
Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer (2014) 1.55
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer (2007) 1.50
Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res (2006) 1.43
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle (2012) 1.41
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther (2009) 1.39
erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol (2003) 1.33
The breast proto-oncogene, HRGalpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland. Oncogene (2002) 1.33
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol (2004) 1.32
ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol (2008) 1.32
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 1.31
Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther (2012) 1.26
The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia (2012) 1.25
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res (2008) 1.23
MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer (2010) 1.18
Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol (2006) 1.17
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle (2011) 1.16
microRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.14
Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. Cancer Res (2005) 1.14
Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol (2009) 1.12
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem (2011) 1.10
New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem (2002) 1.08
Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology (2005) 1.06
ERBB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events. J Biol Chem (2005) 1.04
Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res (2003) 1.03
Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res (2010) 1.03
miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLoS One (2012) 1.02
c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol (2002) 1.02
Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila) (2013) 1.02
Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep (2005) 1.02
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res (2005) 1.02
Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab (2004) 1.02
Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat (2008) 1.01
Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia (2003) 0.99
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol (2009) 0.98
Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci U S A (2002) 0.98
Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol (2002) 0.98
Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Mol Cancer Ther (2005) 0.95
Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-alpha induced apoptosis. Apoptosis (2006) 0.95
Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers. Mod Pathol (2006) 0.94
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med (2014) 0.94
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res (2011) 0.94
The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer (2010) 0.93
Effect of dietary energy restriction on vascular density during mammary carcinogenesis. Cancer Res (2004) 0.93
Steroid receptors and microRNAs: relationships revealed. Steroids (2010) 0.93
Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res (2012) 0.93
Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family. Proc Natl Acad Sci U S A (2003) 0.92
MicroRNA regulation of epithelial plasticity in cancer. Cancer Lett (2012) 0.89
Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. J Biol Chem (2012) 0.89
Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy. Int J Oncol (2005) 0.89
Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. Carcinogenesis (2003) 0.89
Neuregulin receptor ErbB4 functions as a transcriptional cofactor for the expression of surfactant protein B in the fetal lung. Am J Respir Cell Mol Biol (2011) 0.88
Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol (2005) 0.88
Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling. Breast Cancer Res (2014) 0.88